Oncology

Latest News

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health
New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

May 14th 2025

RWJBarnabas Health and Rutgers Cancer Institute unveil the Jack & Sheryl Morris Cancer Center—1 of only 13 freestanding cancer hospitals in the US.

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com
Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com
Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

May 12th 2025

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com
Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

May 12th 2025

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com
HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

May 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Peter P. Yu on Supporting Shared Decision Making
May 31st 2015

Dr Peter P. Yu on Supporting Shared Decision Making

Supporting shared decision making between cancer patients and oncologists starts with an understanding of what the physician's role is, explained Peter P. Yu, MD, FACP, FASCP, president of the American Society of Clinical Oncology and director of cancer research at Palo Alto Medical Foundation.
Site Logo
May 31st 2015

Oncologists Evaluate Costs and Patient Barriers to Cancer Care

Surabhi Dangi-Garimella, PhD
During the Health Services Research and Quality of Care session on the second day of the annual meeting of the American Society of Clinical Oncology, being held at the McCormick Convention Center, Chicago, oncologists discussed barriers to patient participation in cancer clinical trials, and discussed attributes of the high cost of care.
Dr John C. Morris Highlights Exciting Developments in Lung Cancer Immunotherapy
May 31st 2015

Dr John C. Morris Highlights Exciting Developments in Lung Cancer Immunotherapy

The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.
This Week in Managed Care: May 30, 2015
May 30th 2015

This Week in Managed Care: May 30, 2015

This week CMS unveiled its proposed rule to overhaul Medicaid managed care and folded to Florida Governor Rick Scott, and the American Society of Clinical Oncology kicks off its annual meeting in Chicago.
Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer Treatment
May 30th 2015

Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer Treatment

New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD.
Dr Jennifer Malin on the Patient as the Payer in Oncology
May 30th 2015

Dr Jennifer Malin on the Patient as the Payer in Oncology

The move to have patients shoulder greater share of their cost of care is particularly challenging in cancer care, according to Jennifer Malin, MD, medical director for oncology at Anthem.
Site Logo
May 30th 2015

Choosing Ideal Lymphoma Regimens in the Clinic

Surabhi Dangi-Garimella, PhD
On the first day at the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some of the newer agents currently available to treat lymphoma and described their experience with these agents during the session, "Incorporating Novel Agents into Lymphoma Therapy: Value in Everyday Practice."
Site Logo
May 30th 2015

Removing Additional Tissue During Mastectomy Could Reduce Chance of Second Surgery

Laura Joszt, MA
More than half of women diagnosed with breast cancer undergo breast-conserving surgery with a partial mastectomy. A new study from the Yale Cancer Center found that removing more tissue during this procedure could spare thousands of these patients from a second surgery.
Site Logo
May 29th 2015

The World Saw 14.9 million New Cases of Cancer in 2013, Reports JAMA Oncology Study

An international study has estimated that in 2013, there were 14.9 million newly diagnosed cases of cancer and 8.2 million deaths around the world.
Dr Veena Shankaran Discusses Patient-Level Cancer Economics
May 29th 2015

Dr Veena Shankaran Discusses Patient-Level Cancer Economics

Most of the research in cancer economics has been on total cost and cost effectiveness, which is why Veena Shankaran MD, MS, assistant professor in the division of medical oncology at the University of Washington, wanted to have a panel discussion on financial toxicity at the ISPOR 20th Annual Meeting.
Site Logo
May 28th 2015

More Than Half of Younger Cancer Patients Have Tried Alternative Therapies

Laura Joszt, MA
Cancer patients under the age of 65 are much more likely to try alternative and complimentary medicine to ease their symptoms and the side effects of their cancer treatments.
Site Logo
May 28th 2015

Paying, Not Penalizing, Patients to Stay Healthy

A study published in the New England Journals of Medicine evaluated the ability of financial incentives in promoting smoking cessation.
Dr Peter Yu Previews ASCO 2015
May 27th 2015

Dr Peter Yu Previews ASCO 2015

With more than 35,000 people expected to attend the 2015 ASCO Annual Meeting, there are many highly anticipated aspects of the conference; however, Peter P. Yu, MD, FACP, FASCO, president of ASCO and director of Cancer Research at Palo Alto Medical Foundation, highlighted how the society has been going in a different direction with its keynote speaker.
Site Logo
May 27th 2015

Extending Cancer Care Past Remission: The Importance of Cardiac Toxicity Monitoring and Awareness

Constantine A. Mantz, MD
Medical monitoring and counseling can help us track and contain many harmful effects of cancer drug-induced cardiotoxicity. Patient engagement from the very beginning, along with medically advanced testing methods, can help us surmount cardiotoxicity and better ensure that patients receive only the benefits of essential cancer treatment.
Site Logo
May 27th 2015

Cardiovascular Side Effects of Cancer Treatment Demand Attention

Surabhi Dangi-Garimella, PhD
Improved survivorship rates among cancer patients has brought a growing awareness of a serious latent impact of chemotherapy and radiation: cardiotoxicity. Despite extensive research on the subject, our understanding of the tools for identifying and preventing these complications is limited.
Site Logo
May 27th 2015

Importance of a Heart Failure Disease Management Program for Chemotherapy-Induced Toxicity

Anecita Fadol, PhD, RN, FNP, FAANP
To promote collaboration and efficiency, the MD Anderson Cancer Center developed an interdisciplinary team—based Heart Success Program to coordinate the management of concurrent cardiomyopathy and HF while the patient is receiving cancer treatment.
Site Logo
May 27th 2015

PBM Seeks to Tie Drug Price With Outcomes

Steve Miller, MD, chief medical officer of Express Scripts, explained indication-specific pricing as an alternate pricing model for high cost specialty medications like oncology drugs.
Appropriate, Value-Based Care in Immuno-Oncology
May 26th 2015

Appropriate, Value-Based Care in Immuno-Oncology

The Cost of Care in Immuno-Oncology
May 26th 2015

The Cost of Care in Immuno-Oncology

Measuring Response With Immuno-Oncology Agents in NSCLC
May 26th 2015

Measuring Response With Immuno-Oncology Agents in NSCLC

Integrating Immunotherapy in Lung Cancer
May 26th 2015

Integrating Immunotherapy in Lung Cancer

Targeted Therapies and the Sequencing of Immuno-Oncology Drugs
May 26th 2015

Targeted Therapies and the Sequencing of Immuno-Oncology Drugs

The Rationale for Initiating Therapy with an Immuno-Oncology Drug
May 26th 2015

The Rationale for Initiating Therapy with an Immuno-Oncology Drug

Anti-PD-1 Agents as Frontline Therapy
May 26th 2015

Anti-PD-1 Agents as Frontline Therapy

Anti-PD-1 Treatment Selection
May 26th 2015

Anti-PD-1 Treatment Selection

Considerations When Switching Therapy
May 26th 2015

Considerations When Switching Therapy

Determining Appropriate Duration of Treatment
May 26th 2015

Determining Appropriate Duration of Treatment

Sequencing of Immunotherapy in Melanoma
May 26th 2015

Sequencing of Immunotherapy in Melanoma

NRAS Mutations in Melanoma
May 26th 2015

NRAS Mutations in Melanoma

Considerations Related to the Coverage of Immuno-Oncology Therapies
May 26th 2015

Considerations Related to the Coverage of Immuno-Oncology Therapies

<1
...
127128129130131132133134135
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo